Bernadette Jeremiasse

56 statements · 2 topics

Featured statements

Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow.
quote · Breast Cancer
The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time.
quote · Breast Cancer
These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility.
The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid.

Nothing matches these filters — clear the search or widen the filters.

Bernadette's statements about Breast Cancer 28 statements

Open the Breast Cancer collection →

BOB Ped Surg 2023 - Bernadette Jeremiasse, IPSO - Presentation

Statement Achieving complete tumor resections without major complications remains challenging because some tumors are difficult to distinguish from healthy tissue and in other tumors the margin is very narrow. Open
Quotation Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow. Open
Statement Fluorescence guided surgery with tumor-specific probes can visually assist the surgeon in discriminating tumors from healthy tissue. Open
Statement Tumor-specific probes are currently screened one by one and per tumor type. Open
Statement The imaging platform combines tumor organoid biobanks with 3D live imaging and is able to screen fluorescent guided surgery probes in a tumor-specific and patient-specific way. Open
Statement Organoids maintain molecular tumor characteristics and can be held in culture for a long time. Open
Quotation The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time. Open
Statement The platform uses both adult and pediatric tumor organoid biobanks, specifically neuroblastoma and breast cancer. Open
Statement Control organoids were chosen based on the tissue surrounding the tumor: kidney organoids for neuroblastoma and healthy breast organoids for breast cancer. Open
Statement Surface markers upregulated in neuroblastoma or breast cancer were identified based on RNA profiling, the human protein atlas, and literature review. Open
Statement Probes targeting surface markers were conjugated to six different fluorophores ranging between 488 and 647 nanometers. Open
Statement Seven-colored 3D live imaging using confocal microscopy on living organoids was performed, including six probe fluorophores plus the general marker eFluor. Open
Statement Segmentation analysis was performed using the STAPLE pipeline developed in the laboratory, and fluorescent signals were quantified. Open
Statement The three most promising probes for neuroblastoma were validated in vivo using a mouse xenograft model with tumors originating from neuroblastoma organoids. Open
Statement Probe fluorescence varies between patients and even within a patient in neuroblastoma organoid lines. Open
Statement Different probes work on tumor organoids compared to healthy control organoids. Open
Statement The STAPLE pipeline performs 3D segmentation by first segmenting membrane and nuclear signals, generating cells, and combining cells to form single organoids. Open
Statement An organoid is determined to be positive when the intensity of the tumor organoid is at least twice the fluorescence of the healthy control organoid. Open
Quotation The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid. Open
Statement One of the tested probes is advancing to a clinical trial this year. Open
Statement The order of neuroblastoma organoid line performance was similar in vitro and in vivo, with line 129 being highest and line 67 being lowest. Open
Statement Thousands of organoids were quantified using this methodology. Open
Statement Four markers showed promise for neuroblastoma based on high percentages of positive organoids and high fluorescent intensities. Open
Statement The platform can predict which combinations of probes are most promising by screening six probes simultaneously. Open
Statement The three most promising probes tested in vivo for neuroblastoma were GD2, L1CAM, and NCAM. Open
Quotation These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility. Open
Statement These three probes resulted in tumor-to-background ratios above 2, indicating good intraoperative visibility. Open
Statement In vitro imaging patterns resemble the efficacy in vivo, with L1CAM showing higher signal than GD2 in both settings. Open
Bernadette's statements about Pediatric Oncology 28 statements

Open the Pediatric Oncology collection →

BOB Ped Surg 2023 - Bernadette Jeremiasse, IPSO - Presentation

Statement Achieving complete tumor resections without major complications remains challenging because some tumors are difficult to distinguish from healthy tissue and in other tumors the margin is very narrow. Open
Quotation Achieving complete tumor resections without major complications remains challenging. Some tumors, it's difficult to distinguish tumorous tissue from healthy, and in other tumors, the margin is very narrow. Open
Statement Fluorescence guided surgery with tumor-specific probes can visually assist the surgeon in discriminating tumors from healthy tissue. Open
Statement Tumor-specific probes are currently screened one by one and per tumor type. Open
Statement The imaging platform combines tumor organoid biobanks with 3D live imaging and is able to screen fluorescent guided surgery probes in a tumor-specific and patient-specific way. Open
Statement Organoids maintain molecular tumor characteristics and can be held in culture for a long time. Open
Quotation The main advantages of organoids is that they maintain molecular tumor characteristics and can be held in culture for a long time. Open
Statement The platform uses both adult and pediatric tumor organoid biobanks, specifically neuroblastoma and breast cancer. Open
Statement Control organoids were chosen based on the tissue surrounding the tumor: kidney organoids for neuroblastoma and healthy breast organoids for breast cancer. Open
Statement Surface markers upregulated in neuroblastoma or breast cancer were identified based on RNA profiling, the human protein atlas, and literature review. Open
Statement Probes targeting surface markers were conjugated to six different fluorophores ranging between 488 and 647 nanometers. Open
Statement Seven-colored 3D live imaging using confocal microscopy on living organoids was performed, including six probe fluorophores plus the general marker eFluor. Open
Statement Segmentation analysis was performed using the STAPLE pipeline developed in the laboratory, and fluorescent signals were quantified. Open
Statement The three most promising probes for neuroblastoma were validated in vivo using a mouse xenograft model with tumors originating from neuroblastoma organoids. Open
Statement Probe fluorescence varies between patients and even within a patient in neuroblastoma organoid lines. Open
Statement Different probes work on tumor organoids compared to healthy control organoids. Open
Statement The STAPLE pipeline performs 3D segmentation by first segmenting membrane and nuclear signals, generating cells, and combining cells to form single organoids. Open
Quotation The intensity of the tumor organoid must be at least twice the fluorescence of the healthy control organoid. Open
Statement An organoid is determined to be positive when the intensity of the tumor organoid is at least twice the fluorescence of the healthy control organoid. Open
Statement One of the tested probes is advancing to a clinical trial this year. Open
Statement The order of neuroblastoma organoid line performance was similar in vitro and in vivo, with line 129 being highest and line 67 being lowest. Open
Statement Thousands of organoids were quantified using this methodology. Open
Statement Four markers showed promise for neuroblastoma based on high percentages of positive organoids and high fluorescent intensities. Open
Statement The platform can predict which combinations of probes are most promising by screening six probes simultaneously. Open
Statement The three most promising probes tested in vivo for neuroblastoma were GD2, L1CAM, and NCAM. Open
Statement These three probes resulted in tumor-to-background ratios above 2, indicating good intraoperative visibility. Open
Quotation These probes resulted in TBRs, tumor to background ratios above 2, indicating good intraoperative visibility. Open
Statement In vitro imaging patterns resemble the efficacy in vivo, with L1CAM showing higher signal than GD2 in both settings. Open